Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more


(Plasmid #78852)


Item Catalog # Description Quantity Price (USD)
Plasmid 78852 Standard format: Plasmid sent in bacteria as agar stab 1 $85

This material is available to academics and nonprofits only.


  • Vector backbone
  • Backbone size (bp) 14849
  • Modifications to backbone
    espcas9: K848A, K1003A, K1060A
  • Vector type
    Mammalian Expression, Lentiviral, CRISPR
  • Selectable markers
  • Tag / Fusion Protein
    • Cas9-P2A-Puro

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
  • Growth Strain(s)
  • Copy number
    High Copy

Cloning Information

  • Cloning method Restriction Enzyme

Resource Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pLentiCRISPR-E was a gift from Phillip Abbosh (Addgene plasmid # 78852 ; ; RRID:Addgene_78852)
  • For your References section:

    Differential effects of clinically-relevant N- vs C-terminal truncating CDKN1A mutations on cisplatin sensitivity in bladder cancer. Sikder RK, Ellithi M, Uzzo RN, Weader D, Metz AL, Behbahani A, McKenzie ER, El-Deiry WS, Abbosh PH. Mol Cancer Res. 2020 Dec 3. pii: 1541-7786.MCR-19-1200. doi: 10.1158/1541-7786.MCR-19-1200. 10.1158/1541-7786.MCR-19-1200 PubMed 33272936